An inhibitor of Cdk2 and Cdk9
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Fadraciclib

Item No. 36119

Technical Information
Formal Name
(2R,3S)-3-[[6-[[(4,6-dimethyl-3-pyridinyl)methyl]amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-2-pentanol
CAS Number
1070790-89-4
Synonyms
  • CYC065
Molecular Formula
C21H31N7O
Formula Weight
Purity
≥98%
A solid
λmax
213, 231 nm
SMILES
CC[C@H](NC1=NC(NCC2=CN=C(C=C2C)C)=C3N=CN(C(C)C)C3=N1)[C@@H](C)O
InChi Code
InChI=1S/C21H31N7O/c1-7-17(15(6)29)25-21-26-19(18-20(27-21)28(11-24-18)12(2)3)23-10-16-9-22-14(5)8-13(16)4/h8-9,11-12,15,17,29H,7,10H2,1-6H3,(H2,23,25,26,27)/t15-,17+/m1/s1
InChi Key
DLPIYBKBHMZCJI-WBVHZDCISA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    Fadraciclib is an inhibitor of cyclin-dependent kinase 2 (Cdk2) and Cdk9 (IC50s = 4.5 and 20.5 nM, respectively).1 It is selective for Cdk2 and Cdk9 over Cdk1, -4, and -7 (IC50s = 278, 193, and 232 nM, respectively). Fadraciclib inhibits the proliferation of COLO 205 cells (IC50 = 0.31 µM), as well as inhibits proliferation in a panel of five breast cancer cell lines (IC50s = <0.4 µM for all). It decreases phosphorylation of the RNA polymerase II C-terminal domain and RB, Cdk9 and Cdk2 targets, respectively, and induces apoptosis in COLO 205 cells. Fadraciclib (40 and 55 mg/kg) reduces tumor volume in an EoL-1 eosinophilic leukemia mouse xenograft model. It also inhibits tumor growth in an HL-60 mouse xenograft model when administered at a dose of 70 mg/kg.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Frame, S., Saladino, C., MacKay, C., et alFadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLoS One 15(7), e0234103 (2020).